No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% szansa
$129,605 Wol.
$129,605 Wol.
Dec 31, 2026
6% szansa
$129,605 Wol.
$129,605 Wol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Rynek otwarty: May 4, 2026, 10:39 AM ET
Wolumen
$129,605Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$129,605Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania